Is being a Dosimetrist
at risk from AI?

Not in the foreseeable future. While AI can now generate acceptable treatment plans for straightforward cases, dosimetry remains a regulated clinical role requiring human accountability. Radiation oncology is a high-stakes field where errors can cause serious harm, so regulatory bodies and institutions mandate human oversight. AI will shift the role toward quality assurance, complex case management, and interdisciplinary collaboration rather than eliminate it. However, the number of entry-level positions focused solely on routine planning may decline as automation handles more standard cases.

Significant change is already underway. Knowledge-based planning and auto-optimization tools are in clinical use today at many centers, handling 50-70% of routine IMRT and VMAT planning tasks. Over the next 3-5 years, expect adaptive radiotherapy platforms and AI-driven re-planning to become standard, further reducing manual iteration. The role will evolve rather than disappear: fewer dosimetrists may be needed per patient volume, but those who remain will focus on higher-complexity work, QA, and system oversight. Job growth will likely be slower than cancer incidence growth would otherwise predict.

Focus on areas AI cannot easily replicate. Deepen expertise in complex planning scenarios—SBRT, pediatrics, re-irradiation, adaptive therapy—where clinical judgment is paramount. Learn to audit and validate AI-generated plans, understanding when automation succeeds and when it fails. Cross-train in adjacent areas like medical physics (machine QA, dosimetry measurements) or clinical informatics (scripting, data analysis). Develop soft skills: communication with physicians, training junior staff, and leading protocol development. Finally, engage with AI tools directly—understand their limitations and contribute to institutional adoption strategies.

Salaries are unlikely to collapse but may stagnate or grow more slowly. As productivity per dosimetrist increases due to AI assistance, institutions may hire fewer staff or consolidate roles. Dosimetrists who specialize in complex cases or take on hybrid responsibilities (QA, physics support, informatics) will command premium compensation. Entry-level salaries may face downward pressure if the supply of candidates exceeds demand for routine planning roles. Geographic variation will matter: academic centers and large hospital systems investing in advanced technology will value expert dosimetrists, while smaller community clinics may reduce staffing as software improves.

Senior dosimetrists with deep clinical experience and institutional relationships are more resilient. They handle edge cases, mentor staff, lead quality initiatives, and possess judgment that AI cannot replicate. Junior dosimetrists face higher risk if their primary responsibility is generating routine plans—exactly what AI is automating. However, juniors entering the field now have the advantage of learning alongside AI tools from the start, positioning them to become the next generation of AI-savvy experts. The key is to avoid being pigeonholed into purely repetitive work; seek exposure to complex cases and cross-functional projects early.

Yes. Large academic medical centers and comprehensive cancer centers are investing heavily in AI-driven planning and adaptive therapy, creating demand for dosimetrists who can manage these systems and handle complex cases. Smaller community hospitals may adopt turnkey AI solutions that reduce staffing needs. Urban areas with multiple cancer centers offer more opportunities and lateral mobility. Regions with aging populations (higher cancer incidence) will see sustained demand. Internationally, countries with growing radiotherapy infrastructure (parts of Asia, Middle East) may offer opportunities, though regulatory and training requirements vary.

One misconception is that AI will produce perfect plans without human input. In reality, AI optimizes within constraints you define, but it cannot independently weigh clinical priorities or interpret physician intent. Another is that automation will make the job easier across the board—it often shifts work from manual planning to quality assurance, requiring new skills. Finally, some believe regulatory inertia will delay AI adoption indefinitely. While healthcare moves cautiously, AI planning tools are already FDA-cleared and clinically deployed; the question is not if but how fast adoption accelerates. Dosimetrists who underestimate the pace of change risk being unprepared.